Gene · 2348
Papers3,253
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 3,253
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Application of fluorescent tracers in ovarian cancer surgical navigation: a systematic review and meta-analysis. | World J Surg Oncol | 2025 | 40859273 | PubTator, text mining | PubMed |
| Treatable and preventable causes of inborn errors of metabolism: Cohort of neurotransmitter disorders in children from India. | Brain Dev | 2025 | 40840123 | PubTator, text mining | PubMed |
| Evaluation of thymidine kinase 1 and folate receptor alpha as potential biomarkers in prostate cancer. | Sci Rep | 2025 | 40830177 | PubTator, text mining | PubMed |
| Toti-N-glycan Recognition Enables Universal Multiplexed Single-Nucleus RNA Sequencing. | Research (Wash D C) | 2025 | 40809456 | PubTator, text mining | PubMed |
| Utilizing Serum-Derived Lipidomics with Protein Biomarkers and Machine Learning for Early Detection of Ovarian Cancer in the Symptomatic Population. | Cancer Res Commun | 2025 | 40801326 | PubTator, text mining | PubMed |
| Improving the Cellular Accumulation of Folate-Conjugated Fully Chemically Modified siRNAs via 3' Terminal Conjugation. | ACS Omega | 2025 | 40787336 | PubTator, text mining | PubMed |
| Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer. | Front Immunol | 2025 | 40755782 | PubTator, text mining | PubMed |
| Comprehensive assessments of pharmacokinetics and immunogenicity of farletuzumab ecteribulin, a novel antibody-drug conjugate against tumors expressing folate receptor α, in monkeys. | J Pharm Biomed Anal | 2025 | 40752267 | PubTator, text mining | PubMed |
| Antibody-drug conjugates in gynecologic cancer: current landscape, clinical data, and emerging targets. | Int J Gynecol Cancer | 2025 | 40743868 | PubTator, text mining | PubMed |
| Pembrolizumab and lenvatinib in the treatment of recurrent ovarian carcinoma: A single institution experience. | Gynecol Oncol Rep | 2025 | 40740417 | PubTator, text mining | PubMed |
| Breaking Tumor Chemoresistance via METTL3 Regulation Enhanced by Sequential Delivery of Dexamethasone. | ACS Appl Mater Interfaces | 2025 | 40736404 | PubTator, text mining | PubMed |
Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system. | Immunother Adv | 2025 | 40735486 | PubTator, text mining | PubMed |
| Rationale Design of a Zn(II)-Coordinated, Cell Penetrating, and Functionalized Tetrapeptide Self-Assembly for Delivery of Chemotherapeutic Drugs to Folic Acid Receptor-Expressing Cancer Cells. | ACS Appl Bio Mater | 2025 | 40734540 | PubTator, text mining | PubMed |
| Optimization and Validation of a Folate Ligand-Targeted qPCR Method for Detection of Folate Receptor-Positive Circulating Tumor Cells in Gastric Cancer. | Asian Pac J Cancer Prev | 2025 | 40729092 | PubTator, text mining | PubMed |
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer. | Gynecol Oncol | 2025 | 40700855 | PubTator, text mining | PubMed |
| Advancing precision antibody-drug conjugate therapy: unique proteogenomic profiles of tumor subsets in non-small cell lung cancer. | Exp Hematol Oncol | 2025 | 40646627 | PubTator, text mining | PubMed |
A novel truncated mutation in folate receptor α (FRα) affecting its glycosylation and affinity for folate in a consanguineous family with progressive encephalopathy: follow up and treatment improvement. | Mol Biol Rep | 2025 | 40643761 | PubTator, text mining | PubMed |
| Challenges and perspectives of CAR-T cell therapy in solid tumours: insights from gastric cancer. | Br J Cancer | 2025 | 40615715 | PubTator, text mining | PubMed |
| Update Gynecologic Malignancies 2025 - Expert Opinion on Systemic Therapy for Early and Advanced Gynecological Cancers. | Geburtshilfe Frauenheilkd | 2025 | 40599899 | PubTator, text mining | PubMed |
| XGB-BIF: An XGBoost-Driven Biomarker Identification Framework for Detecting Cancer Using Human Genomic Data. | Int J Mol Sci | 2025 | 40565055 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2348/papers?page=12